Placebo News and Research

RSS

Study demonstrates potential therapeutic use of ketamine for alcohol addiction

A study shows one-off dose of ketamine could help heavy drinkers reduce alcohol intake by ‘erasing’ drink-related memories.

26 Nov 2019

FDA-approved drug to prevent organ rejection may slow skin aging

The search for youthfulness typically turns to lotions, supplements, serums and diets, but there may soon be a new option joining the fray.

25 Nov 2019

Inhaled cannabis cuts headache and migraine severity by nearly half

Inhaled cannabis reduces self-reported headache severity by 47.3% and migraine severity by 49.6%, according to a recent study led by Carrie Cuttler, a Washington State University assistant professor of psychology.

25 Nov 2019

New targeted treatment for insomnia has fewer side effects

Insomnia is one of the most common sleep disorders, and is most commonly treated with hypnotics. However, hypnotics have motor and cognitive side effects.

22 Nov 2019

Investigational drug for treating patients with treatment-resistant epilepsy

Imagine not being able to drive, shower alone or even work because you are never quite sure when the next seizure will leave you incapacitated.

21 Nov 2019

Omega 3 fish oil supplements may benefit some children with ADHD

A team of researchers from King's College London collaborated with colleagues from China Medical University in Taichung, Taiwan to find that omega-3 fish oil supplements could benefit children with Attention Deficit Hyperactivity Disorder (ADHD). Their work was published in the latest issue of the journal Translational Psychiatry.

20 Nov 2019

BrainStorm publishes NurOwn ALS Phase 2 randomized clinical trial results in Neurology

BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.

20 Nov 2019

JACM special issue focuses on challenges in inter-rater reliability in Traditional Chinese Medicine

Diagnostic agreement between practitioners is an ongoing challenge in the evaluation of Traditional Chinese Medicine and other healthcare systems that rely on constitutional types.

20 Nov 2019

ETVAX vaccine candidate shows promise against enterotoxigenic E. coli diarrhea

University of Gothenburg reports first successful results of the oral, inactivated vaccine candidate ETVAX against enterotoxigenic E. coli diarrhea in a placebo-controlled phase I/II study in infants and children from 6 months to 5 years of age in Bangladesh.

20 Nov 2019

New drug 'ubrogepant' may work for migraine

A new study published in the November 19, 2019 issue of JAMA shows that a newly developed small molecule drug called ubrogepant may successfully fight migraine at doses of 25 and 50 mg, with pain relief at 2 hours with both doses, while the most troublesome symptom of migraine was held off at 2 hours post-dose with the 50 mg dose. This may help millions of migraine patients to achieve pain relief and function better.

19 Nov 2019

Study shows how a potent psychedelic changes our waking brain waves

Scientists have peered inside the brain to show how taking DMT affects human consciousness by significantly altering the brain's electrical activity.

19 Nov 2019

Nutraceuticals could help prevent diabetes

Diabetes mellitus is among the fastest-growing conditions in the world, and in Australia, a new case is diagnosed every 5 minutes. Many people with this illness are now taking diet supplements in an attempt to prevent this condition.

17 Nov 2019

Clinical trial: Oral drug improves exercise capacity in teens with congenital heart defects

The largest-ever clinical trial of a medication for pediatric cardiology patients found that an oral drug significantly improved exercise capacity in adolescent patients with severe, congenital single-ventricle heart defects.

17 Nov 2019

Experimental drug found to be effective at reducing bad cholesterol

Twice-yearly injections of an experimental cholesterol-lowering drug, inclisiran, were effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol, in patients already taking the maximum dose of statin drugs, according to data of the ORION-10 trial presented Saturday, Nov. 16, at the American Heart Association's Scientific Sessions 2019.

17 Nov 2019

Study shows link between inflammation and mental sluggishness

Scientists at the University of Birmingham in collaboration with the University of Amsterdam have uncovered a possible explanation for the mental sluggishness that often accompanies illness.

15 Nov 2019

New treatment stops peanut allergy for 6 weeks with single dose

A small study published in the journal JCI Insight on November 14, 2019, suggests that antibody treatment could help people with severe allergy to peanuts eat a small amount of peanut-containing food just two weeks later, without any ill effects. This seems to show that this is a safe, fast and effective treatment for food allergy.

14 Nov 2019

Targeting the formation of alpha-synuclein aggregates may slow Parkinson's progression

Aggregates of the protein alpha-synuclein arising in the gut may play a key role in the development of Parkinson's disease.

13 Nov 2019

Russian scientists explain how an additional component can triple vaccine efficiency

A team of Russian scientists carried out a study on the cell immunity level and found out how an adjuvant called azoximer bromide increases the immunogenicity of the anti-flu vaccine.

12 Nov 2019

Young male cancer survivors may benefit from testosterone replacement therapy

Young male cancer survivors may significantly benefit from testosterone replacement therapy - especially after testicular cancer - according to the first ever clinical trial of its kind.

12 Nov 2019

Regulating gut bacteria could calm chemo side effects, reduce cognitive problems

In a new study, scientists observed several simultaneous reactions in mice given a common chemotherapy drug: Their gut bacteria and tissue changed, their blood and brains showed signs of inflammation, and their behaviors suggested they were fatigued and cognitively impaired.

11 Nov 2019

Placebo News and Research

Study demonstrates potential therapeutic use of ketamine for alcohol addiction

FDA-approved drug to prevent organ rejection may slow skin aging

Inhaled cannabis cuts headache and migraine severity by nearly half

New targeted treatment for insomnia has fewer side effects

Investigational drug for treating patients with treatment-resistant epilepsy

Omega 3 fish oil supplements may benefit some children with ADHD

BrainStorm publishes NurOwn ALS Phase 2 randomized clinical trial results in Neurology

JACM special issue focuses on challenges in inter-rater reliability in Traditional Chinese Medicine

ETVAX vaccine candidate shows promise against enterotoxigenic E. coli diarrhea

New drug 'ubrogepant' may work for migraine

Study shows how a potent psychedelic changes our waking brain waves

Nutraceuticals could help prevent diabetes

Clinical trial: Oral drug improves exercise capacity in teens with congenital heart defects

Experimental drug found to be effective at reducing bad cholesterol

Study shows link between inflammation and mental sluggishness

New treatment stops peanut allergy for 6 weeks with single dose

Targeting the formation of alpha-synuclein aggregates may slow Parkinson's progression

Russian scientists explain how an additional component can triple vaccine efficiency

Young male cancer survivors may benefit from testosterone replacement therapy

Regulating gut bacteria could calm chemo side effects, reduce cognitive problems

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News